Clinical trial
Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. a Dose Escalation, Open-label, Phase I Study.
NCT05054257 is registered in ClinicalTrials.gov with Institute of Hematology and Blood Transfusion, Czech Republic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. a Dose Escalation, Open-label, Phase I Study.
- Lead sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- June 2, 2021
- Completion date
- December 12, 2025
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-hodgkin's lymphoma refractory, non-hodgkin's lymphoma, relapsed, relapsed or refractory b-cell acute lymphoblastic leukemia